ALVO
Alvotech·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 3
Bearish signal 1
Stock Price Surged Significantly
Consensus Rating "Strong Buy"
High Gross Profit Margin
Bearish Abandoned Baby
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About ALVO
Alvotech
A global biotech company that develops and manufactures biosimilar medicines
9, Rue de Bitbourg, L-1273 Luxembourg, Grand Duchy of Luxembourg
--
Alvotech was incorporated on 23 August 2021 under the laws of the Grand Duchy of Luxembourg. The company is a biotechnology company founded by Robert Wessman focused on developing and manufacturing biosimilars for patients worldwide. The company seeks to become a global leader in biosimilars through a fully integrated approach and extensive in-house capabilities by providing high-quality, cost-effective products and services. The company's current pipeline contains eight biosimilar drug candidates designed to treat autoimmune diseases, eye diseases, osteoporosis, respiratory diseases and cancer.
Earnings Call
Q1/2025
Estimate EPS0.03
Actual EPS0.35
Estimate Revenue95.02M
Actual Revenue109.91M
Alvotech's Q1 2025 Earnings Call: Unpacking Contradictions on Market Dynamics, Pricing Strategies, and Biosimilar Launches
May 19,2025 09:15
Earnings Decrypt
Earnings Decrypt
Q2/2025
Estimate EPS0
Actual EPS--
Estimate Revenue120.51M
Actual Revenue--
Alvotech's Q2 2025: Navigating Contradictions in Market Share, Revenue Guidance, and FDA Inspections
Aug 14,2025 11:44
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
ALVO has released its 2025 Q3 earnings. EPS was reported at -0.02, versus the expected -0.01, missing expectations. The chart below visualizes how ALVO has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
ALVO has released its 2025 Q3 earnings report, with revenue of 113.86M, reflecting a YoY change of 10.56%, and net profit of -5.25M, showing a YoY change of 53.90%. The Sankey diagram below clearly presents ALVO's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
